Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.
BörsenkürzelTBPH
Name des UnternehmensTheravance Biopharma Inc
IPO-datumMay 16, 2014
CEOMr. Rick E. Winningham
Anzahl der mitarbeiter97
WertpapierartOrdinary Share
GeschäftsjahresendeMay 16
AddresseUgland House, South Church Street
StadtGEORGE TOWN
BörseNASDAQ Global Market Consolidated
LandCayman Islands
PostleitzahlKY1-1104
Telefon16508086000
Websitehttps://www.theravance.com/
BörsenkürzelTBPH
IPO-datumMay 16, 2014
CEOMr. Rick E. Winningham
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten